Sign in
CompletedNo phase

Efficacy of Trigeminal Nerve Stimulation for ADHD

Key facts

Who runs it
University of California, Los Angeles
Where
Los Angeles and Seattle, United StatesSee the 2 sites
Trial code
Status
Completed
People taking part
218 people enrolled
Started
1 Sept 2022
Ended
10 Apr 2026
Type of study
Interventional, 2 groupsOne group gets a sham (pretend) treatment, for comparison.
Treatments tested
  • Active eTNS
  • Sham eTNS
Record updated
14 May 2026

Who can take part

Age
7 years to 12 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 13 criteriaShow less

Who can take part

  • male and female children ages 7 to 12 years with DSM-5 ADHD, any current presentation, as determined by diagnostic interview, Kiddie Schedule for Affective Disorders and Schizophrenia (KSADS), and clinical interview
  • total score >= 24 on baseline ADHD-RS
  • CGI-S score at baseline >= 4
  • no current medication with CNS effects (Participants previously on psychostimulant medication will be required to be not optimally treated and off medication for one week or 5 half-lives for all other medications); stable use of supplements will be permitted
  • parents able and willing to monitor proper use of the stimulation device and complete all required rating scales
  • estimated Full Scale IQ >= 80 based on WASI subtests
  • parent and participant able to complete rating scales and other measures in English
  • able to cooperate during EEG

Who cannot take part

  • impaired functioning to a degree that requires immediate initiation of ADHD medication in the opinion of the parents and/or investigator
  • current diagnosis of autism spectrum disorder or major depression
  • history of lifetime psychosis, mania, or seizure disorder
  • history of seizure disorder or head injury with loss of consciousness
  • baseline suicidality

Where in United States

  • University of California, Los AngelesLos Angeles, United States
  • Seattle Children's HospitalSeattle, United States

About the trial

What the trial wants to find out

This study is a large multisite randomized clinical trial to asses the efficacy of external trigeminal nerve stimulation (TNS), a novel, minimal risk, non-invasive neuromodulation treatment, for ADHD in children ages 7-12 years old (N=180).

Read full original descriptionShow less

Study hypotheses address potential differences in ADHD symptoms over 4 weeks treatment with active vs. sham TNS in an expanded multi-site investigation; whether resting state fronto-parietal connectivity mediates TNS impact on ADHD symptoms; if changes in fronto-parietal activation, as measured by electroencephalography (EEG), predict TNS-related treatment outcomes; and whether a baseline cognitive profile similarly predicts response to TNS therapy.

The 2 groups in the trial

  • Active eTNSTreatment being tested

    Following screening and determination of eligibility , participants at baseline are randomized to receive 4 weeks nightly treatment with active eTNS. Positive responders will be invited to participate in a 12-month open-label continuation phase.

  • Sham eTNSSham treatment, for comparison

    Following screening and determination of eligibility, participants at baseline are randomize to receive 4 weeks nightly treatment with sham eTNS. At conclusion of the double-blind phase, participants randomized to sham will be provided an opportunity to receive an additional 4 weeks nightly treatment with active eTNS. Positive responders to active eTNS will be invited to participate in a 12-month open-label continuation phase.

    Treatment: Active eTNS and Sham eTNS

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Efficacy of External Trigeminal Nerve Stimulation for Treatment of ADHD
Record updated
14 May 2026